Although previous studies have indicated a limited efficacy of activating individual PPARs, ongoing clinical trials show that dual and pan-PPAR agonists might serve as promising strategies for NASH therapy. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.